Griswold Group: Biomolecular Antimicrobial Therapies

 

Several projects in the lab are focused on developing enzymes for use as antimicrobial agents in treating a variety of bacterial infections. Using directed evolution and other technologies, we are engineering therapeutic candidates to meet the following design specifications:

  • biocidal activity towards drug resistant pathogens
  • decreased immunogenicity in the context of the human immune system
  • improved capacity to degrade bacterial biofilms